CCR5 Antagonist Development Meeting Postponed
This article was originally published in The Pink Sheet Daily
FDA and the Forum for Collaborative HIV Research have postponed a meeting to discuss CCR5 antagonist development until February or March in order to analyze new data
You may also be interested in...
FDA and the Forum for Collaborative HIV Research will hold a public meeting on Jan. 18 to discuss the appropriate collection of long-term follow-up data for CCR5 antagonist clinical trials.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.